Illumina (NASDAQ:ILMN) Director Keith Meister Sells 104,393 Shares

Posted by Francis Steltz on May 15th, 2026

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) Director Keith Meister sold 104,393 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $145.34, for a total value of $15,172,478.62. Following the transaction, the director owned 3,500,048 shares of the company’s stock, valued at approximately $508,696,976.32. This trade represents a 2.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Illumina Price Performance

ILMN stock opened at $143.24 on Friday. The stock has a 50-day moving average price of $128.31 and a two-hundred day moving average price of $129.43. The stock has a market cap of $21.67 billion, a PE ratio of 26.04, a price-to-earnings-growth ratio of 2.40 and a beta of 1.42. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 1 year low of $78.55 and a 1 year high of $155.53.

Illumina (NASDAQ:ILMN – Get Free Report) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities analysts forecast that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Illumina

Several hedge funds have recently bought and sold shares of ILMN. Empowered Funds LLC lifted its stake in Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in Illumina in the 2nd quarter valued at about $621,000. CW Advisors LLC acquired a new stake in Illumina in the 2nd quarter valued at about $275,000. Marshall Wace LLP lifted its stake in Illumina by 49.0% in the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC lifted its stake in Illumina by 30.9% in the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after purchasing an additional 1,748 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently commented on ILMN. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research note on Thursday. Citigroup increased their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Weiss Ratings downgraded shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Robert W. Baird set a $137.00 price objective on shares of Illumina in a research note on Friday, February 6th. Finally, Stifel Nicolaus increased their price objective on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Seven research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $137.75.

View Our Latest Stock Analysis on Illumina

About Illumina

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.